It's been another tough week for ASX healthcare but Morgans' Scott Power said there's been bright spots with Racura soaring on trial news.

In a report released yesterday, Vamil Divan from Guggenheim reiterated a Buy rating on ANI Pharmaceuticals, with a price target of $124.00. The company’s shares closed yesterday at $72.17. Divan ...

Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On ...

Vertex stock jumps after interim phase III data show povetacicept cuts proteinuria 52% in IgA nephropathy study and boost hopes for accelerated FDA approval.

Vertex Pharmaceuticals has a rolling biologics license application with the FDA for povetaciceptin IgA nephropathy. With new data from RAINIER, the biotech expects to complete its submission by the ...

Vertex acquired the drug in a $4.9bn takeover of Alpine Immune Sciences in April 2024. Credit: JHVEPhoto / Shutterstock.com Vertex Pharmaceuticals will head to US regulators after its immunoglobulin A ...

These Irish pubs have kept their doors open for centuries and proudly wear their age on their walls, all while serving up delicious pints of Guinness.

The new study estimated it would cost $173 million to implement all RUSP-approved conditions across all 50 states, including those added in late 2025 and two anticipated future conditions.

Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the best stocks for beginners with little money in 2026. On February 19, Travere Therapeutics reported earnings for Q4 and full-year 2025, ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

Travere Therapeutics (NASDAQ:TVTX) highlighted record demand for FILSPARI in IgA nephropathy (IgAN), provided an update on ...